Related Experiment Video
Updated: Nov 15, 2025

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
Targetable pathogenic mechanisms in nasal polyposis
Alexander L Schneider1, Robert P Schleimer1,2, Bruce K Tan1,2
1Department of Otolaryngology, Head and Neck Surgery, Chicago, Illinois, USA.
Abstract:
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.
Insights
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex condition. This review explores new targeted therapies beyond type 2 inflammation for CRSwNP, examining ongoing clinical studies.
Area of Science:
- Immunology
- Otolaryngology
- Pharmacology
Background:
- Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently recurs despite treatment.
- Current CRSwNP biologics target type 2 inflammation, but other pathways may be involved.
Purpose of the Study:
- To review pathogenic mechanisms in CRSwNP.
- To discuss ongoing clinical trials of targeted therapeutics for CRSwNP.
Main Methods:
- Literature review of CRSwNP pathophysiology.
- Analysis of ongoing clinical studies for targeted therapies.
- Exploration of therapeutic targets in related inflammatory diseases.
Main Results:
- Type 2 inflammation is a primary target of current CRSwNP biologics.
- Other inflammatory pathways in CRSwNP warrant investigation for targeted therapies.
- Clinical trials are evaluating novel targeted agents for CRSwNP.
Conclusions:
- Understanding diverse CRSwNP pathogenic mechanisms is crucial.
- Targeted therapeutics beyond type 2 inflammation hold promise for CRSwNP treatment.
- Further research into non-type 2 pathways may yield new therapeutic options.
More Related Videos
07:36Contact-Free Co-Culture Model for the Study of Innate Immune Cell Activation During Respiratory Virus Infection
Published on: February 28, 2021
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Single Nucleotide Polymorphisms-SNPs
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: